#Canada #Dana Point #Pacific Software #PurMinds Holdings #neuro-medicine

Pacific Software Inc. Acquires PurMinds Holdings

Pacific Software Inc., a notable player in the OTC markets, recently made headlines by announcing the acquisition of PurMinds Holdings Inc., specifically encompassing its subsidiary 10763942 Canada Inc. This strategic move, revealed to the public on August 25, 2025, is part of an effort to bolster Pacific Software's stance in the innovative field of neuro-medicine.

The acquisition includes PurMinds™ products, a series of cutting-edge therapeutic solutions aimed at treating neurological and psychiatric disorders. According to CEO Harrysen Mittler, this transaction will significantly enhance the growth trajectory of 10763942 Canada Inc., consequently maximizing shareholder value.

Significance of the Acquisition

10763942 Canada Inc., recognized as a pioneer in neuro-medicine, is on a mission to revolutionize the treatment of patients suffering from a variety of neurological conditions. The company's focus lies in developing precise neuromedicine solutions that address critical global health care needs. With an advanced pipeline primarily composed of small molecules and psychoactive compounds, PurMinds aims to target issues such as neuroinflammation and reduced neuroplasticity, which are prevalent in numerous neurological disorders.

The strategic partnership formed by PurMinds with world-leading technology firms is poised to play a crucial role in the development of next-generation employee assessment and diagnostic solutions for neurological patients. This partnership lays the groundwork for global commercialization, projected to commence in the short to medium term, enhancing both innovation and accessibility to new treatments.

Future Outlook and Leadership Changes

As part of the transition, the current management team from 107 Canada is expected to undertake leadership roles within Pacific Software Inc. Furthermore, the formation of a new Board of Directors will likely involve deliberations regarding a potential name change for the company to “PurMinds Enterprises.”

Janet Qi, Founder and CEO of PurMinds, underscored the monumental importance of this merger, stating, “This business combination signifies a landmark moment for PurMinds and 107 Canada.” Qi highlighted that both companies' clinical programs have reached a pivotal developmental stage, with GMP-grade production of botanical psilocybin nearing fulfillment in collaboration with established partners. The integration into a publicly traded company opens new avenues for capital access, operational expansion, and stakeholder value enhancement.

About PurMinds™ and Its Vision

Established in Ontario, Canada, in May 2018, PurMinds is committed to advancing the frontier of neuro-medicine through the development of genuine solutions for neurological and psychiatric disorders. The clinical pipeline includes innovative neuroprotective compounds designed to restore neuronal functions across multiple clinical indications where patient needs are not currently met. The company was awarded a Controlled Drugs and Substances License by Health Canada in 2020, allowing it to further its research and development in a regulated environment.

PurMinds models a business strategy that emphasizes long-term value creation through drug development focused on therapeutics that encourage neuroplasticity while also establishing short- and mid-term revenue avenues through precision medicine tools related to early detection and risk assessment of neurological conditions.

In conclusion, the acquisition by Pacific Software Inc. of both PurMinds Holdings and its robust product portfolio marks a progressive step within the neuro-medicine domain. As these entities synergize their resources, enhanced innovation and market penetration in medicinal solutions for neurological patients can be anticipated in the near future.